# BioLoomics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bioloomics

- Industry: Biotechnology
- Headquarters: Boulder, US
- Website: www.bioloomics.com
- Total disclosed funding: $8.7M
- Latest round: Seed (Sep 19, 2023)
- Investors on record: 7

## About

Founded in 2019 by its CEO, Doug Chapnick, and co-founders, Jeremy Jacobsen and Ted Kee, and based in Colorado, US, BioLoomics, Inc., operates as a biotechnology company focused on the evolution of antibodies in human cells. In September 2023, BioLoomics, Inc., raised USD 8.7 million in seed funding led by Innovation Endeavors, with participation from Boom Capital Ventures, BoxOne Ventures, GC&H Investments, Horizons Ventures, Hummingbird Ventures, and TechU Ventures.

The company offers drug discovery tools and protein drugs used to accelerate the rate of discovery of promising drug activity, enabling the development of safer and more efficient cancer treatments.

The company uses synthetic biology, artificial intelligence (AI), imaging, and robotics technology to conduct activity-guided antibody library screening.

The company plans to use the September 2023 funding to support the development of its pre-clinical assets.

## Funding rounds

- Seed, Sep 19, 2023, $8.7M — Hummingbird Ventures, Innovation Endeavors, Horizons Ventures, TechU Ventures, GC&H Investments, BoxOne Ventures, Boom Capital Ventures

## Investors

- Hummingbird Ventures (https://capitalatlas.ai/funds/hummingbird-ventures) — Seed
- Innovation Endeavors (https://capitalatlas.ai/funds/innovation-endeavors) — Seed
- Horizons Ventures — Seed
- TechU Ventures (https://capitalatlas.ai/funds/techu-ventures) — Seed
- GC&H Investments (https://capitalatlas.ai/funds/gc-h-investments) — Seed
- BoxOne Ventures (https://capitalatlas.ai/funds/boxone-ventures) — Seed
- Boom Capital Ventures — Seed